

Author	Publication	Year	Country	Design	Mono/Multicenter	NOS	Number of Patients
Hartery	Full text	2016	Ireland	Retrospective	Mono	5	5
Lim	Full text	2016	UK	Retrospective	Mono	5	5
Wright	Full text	2017	US	Retrospective	Mono	6	10
Olmedo-Martin	Full text	2017	Spain	Retrospective	Mono	4	2
Mumtaz	Case Reports	2016	UK	Retrospective	Mono	4	1
Peverelle	Abstract	2018	Australia	Retrospective	Mono	4	5
Drastich	Abstract	2018	Czech Republic	Retrospective	Mono	3	2
Daffra	Abstract	2017	Argentina	Retrospective	Mono	3	1

Supplementary table 1. Studies characteristics.

Reference	Mean Age (years)	Male	UC	CD	Time between LT and VDZ start (mean months)	Time between LT and VDZ start (range months)	Previous anti-TNF agents (n)	Previous infections (n)
Hartery 2016	NA	4	4	1	69.16	38.4 - 117.6	2	0
Lim 2016	42.4	4	5	0	73.9	10.8 - 159.6	4	0
Wright 2017	44.0	8	8	2	57.2	0 - 186	4	NA
Olmedo-Martin 2017	36.0	0	2	0	46.5	35 - 58	2	2
Mumtaz 2016	22.0	0	1	0	NA	NA	0	1
Peverelle 2018	NA	4	4	1	NA	NA	NA	NA
Drastich 2018	32.0	2	2	0	NA	NA	2	2
Daffra 2017	20.0	1	1	0	42.0	NA	1	0

Supplementary table 2. Baseline characteristics. UC: ulcerative colitis; CD Crohn's Disease; VDZ: Vedolizumab; LT: Liver transplantation; TNF: tumor necrosis factor; n: number of patients.

Reference	Clinical response (n)	Clinical remission (n)	Mucosal healing (n)	No response (n)	Colectomy (n)
Hartery 2016	3	2	2	2	2
Lim 2016	\	\	\	\	\
Wright 2017	6	\	\	4	2
Olmedo-Martin 2017	2	2	2	0	0
Mumtaz 2016	1	1	1	0	0
Peverelle 2018	5	5	5	0	0
Drastich 2018	2	2	2	0	0
Daffra 2017	1	1	1	0	0

Supplementary table 3. Inflammatory Bowel Disease treatment outcomes; n: number of patients.